vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ServisFirst Bancshares, Inc. (SFBS). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $159.0M, roughly 1.8× ServisFirst Bancshares, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 52.2%, a 44.1% gap on every dollar of revenue. Over the past eight quarters, ServisFirst Bancshares, Inc.'s revenue compounded faster (17.7% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
ACAD vs SFBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $159.0M |
| Net Profit | $273.6M | $83.0M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 52.2% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | 90.3% | 31.2% |
| EPS (diluted) | $1.61 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $159.0M | ||
| Q4 25 | $284.0M | $162.2M | ||
| Q3 25 | $278.6M | $136.3M | ||
| Q2 25 | $264.6M | $132.1M | ||
| Q1 25 | $244.3M | $131.8M | ||
| Q4 24 | $259.6M | $131.9M | ||
| Q3 24 | $250.4M | $123.7M | ||
| Q2 24 | $242.0M | $114.8M |
| Q1 26 | — | $83.0M | ||
| Q4 25 | $273.6M | $86.4M | ||
| Q3 25 | $71.8M | $65.6M | ||
| Q2 25 | $26.7M | $61.4M | ||
| Q1 25 | $19.0M | $63.2M | ||
| Q4 24 | $143.7M | $65.2M | ||
| Q3 24 | $32.8M | $59.9M | ||
| Q2 24 | $33.4M | $52.1M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 66.3% | ||
| Q3 25 | 12.8% | 57.8% | ||
| Q2 25 | 12.2% | 58.0% | ||
| Q1 25 | 7.9% | 60.0% | ||
| Q4 24 | 59.1% | 60.2% | ||
| Q3 24 | 12.6% | 58.5% | ||
| Q2 24 | 12.6% | 58.0% |
| Q1 26 | — | 52.2% | ||
| Q4 25 | 96.3% | 59.0% | ||
| Q3 25 | 25.8% | 48.1% | ||
| Q2 25 | 10.1% | 46.5% | ||
| Q1 25 | 7.8% | 48.0% | ||
| Q4 24 | 55.4% | 52.9% | ||
| Q3 24 | 13.1% | 48.4% | ||
| Q2 24 | 13.8% | 45.4% |
| Q1 26 | — | $1.52 | ||
| Q4 25 | $1.61 | $1.58 | ||
| Q3 25 | $0.42 | $1.20 | ||
| Q2 25 | $0.16 | $1.12 | ||
| Q1 25 | $0.11 | $1.16 | ||
| Q4 24 | $0.86 | $1.19 | ||
| Q3 24 | $0.20 | $1.10 | ||
| Q2 24 | $0.20 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $1.8B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.9B |
| Total Assets | $1.6B | $18.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.2B | $1.8B | ||
| Q3 25 | $917.3M | $1.8B | ||
| Q2 25 | $822.4M | $1.7B | ||
| Q1 25 | $765.2M | $1.7B | ||
| Q4 24 | $732.8M | $1.6B | ||
| Q3 24 | $577.2M | $1.6B | ||
| Q2 24 | $516.7M | $1.5B |
| Q1 26 | — | $18.2B | ||
| Q4 25 | $1.6B | $17.7B | ||
| Q3 25 | $1.3B | $17.6B | ||
| Q2 25 | $1.2B | $17.4B | ||
| Q1 25 | $1.1B | $18.6B | ||
| Q4 24 | $1.2B | $17.4B | ||
| Q3 24 | $976.9M | $16.4B | ||
| Q2 24 | $914.1M | $16.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $355.2M | ||
| Q3 25 | $74.3M | $140.9M | ||
| Q2 25 | $64.0M | $67.6M | ||
| Q1 25 | $20.3M | $48.0M | ||
| Q4 24 | $40.4M | $252.9M | ||
| Q3 24 | $63.2M | $84.0M | ||
| Q2 24 | $25.0M | $48.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 4.11× | ||
| Q3 25 | 1.03× | 2.15× | ||
| Q2 25 | 2.40× | 1.10× | ||
| Q1 25 | 1.07× | 0.76× | ||
| Q4 24 | 0.28× | 3.88× | ||
| Q3 24 | 1.93× | 1.40× | ||
| Q2 24 | 0.75× | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
